Pangenomic Study During Alcoholic Cirrhosis

Alcoholic Cirrhosis Clinical Trial

— CDCHC  

Official title:

Genetical Predisposition in Hepatocellular Carcinoma : Pangenomic Link Study During Alcoholic Cirrhosis

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01065233
• Other study ID #: BRD/07/08-M
• Status: Completed
• Start date: October 23, 2008
• Est. completion date: July 20, 2013

Study information

• Verified date: September 2021
• Source: Nantes University Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Hepatocellular carcinoma (HCC) is a frequent complication of cirrhosis. Occurrence of HCC could be linked with multiple functional region of genome.

The determining of a genomic mapping of " single nucleotide polymorphisms " (SNPs) permit to perform some genetic link studies with pathologies without clear hereditary disposition.

In this study, the investigators will identify predictives genetic polymorphism of HCC.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 1325
• Est. completion date: July 20, 2013
• Est. primary completion date: December 27, 2011
• Accepts healthy volunteers: No
• Gender: All
• Age group: 35 Years to 70 Years

Eligibility

Inclusion Criteria:

• 35 to 70 years old

• Compensated cirrhosis or not

• Caucasian origin of the parents

• Patient with cirrhosis (histological proof or obvious)

Exclusion Criteria:

• HIV, HBV, HCV positive

• Known Homozygotia (C282Y+/+)

• Important hepatocytary iron overload for patient with resection

• HCC non histologically prooved

Related Conditions & MeSH terms

• Alcoholic Cirrhosis
• Fibrosis
• Liver Cirrhosis
• Liver Cirrhosis, Alcoholic

Intervention

Genetic:
• DNA extraction
DNA extraction of blood sample for DNAship analysis

Locations

Country	Name	City	State
France	Nantes UH	Nantes
France	Jean Verdier UH	Paris
France	Paul Brousse UH	Paris
France	Rennes UH	Rennes

Sponsors (1)

Lead Sponsor	Collaborator
Nantes University Hospital

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Existence of HCC and Pangenomic analysis of DNA polymorphism	Existence of HCC and determination of which genetic polymorphism are predisposing to HCC or preventing for HCC
Secondary	cirrhosis severity (compensated or not)	Analysis of the genetic polymorphism involved in the severity of cirrhosis